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Abstract 
 
Background: Inflammatory markers such as C-reactive protein (CRP) and interleukin-6 have been linked 
with an increased risk of sudden cardiac death (SCD), but the relationship between fibrinogen and SCD is 
uncertain. We aimed to assess the association between fibrinogen and SCD. 
Methods: Plasma fibrinogen was measured at baseline in a prospective cohort of 1773 men aged 42-61 
years free of heart failure or cardiac arrhythmias that recorded 131 SCDs during 22 years follow-up. 
Correction for within-person fibrinogen variability was made using data from repeat measurements taken 
years apart.  
Results: Fibrinogen was strongly correlated with CRP, weakly correlated with several cardiovascular risk 
markers, and was log-linearly associated with SCD risk. In analyses adjusted for conventional risk 
factors, the hazard ratio (HR) (95% CIs) for SCD per 1 standard deviation (SD) higher baseline loge 
fibrinogen was 1.32 (1.11-1.57). The results remained consistent on further adjustment for alcohol 
consumption, resting heart rate, and circulating lipids 1.30 (1.09-1.56). The corresponding HRs were 1.80 
(1.25-2.58) and 1.74 (1.20-2.52) after correction for within-person variability. HRs remained unchanged 
on further adjustment for CRP and accounting for incident coronary events. In a meta-analysis of three 
cohort studies, the fully-adjusted relative risks for SCD per 1 SD higher baseline and long-term 
fibrinogen levels were 1.42 (1.25-1.61) and 2.07 (1.59-2.69) respectively. The associations were similar 
for non-SCDs in both cohort analysis and the meta-analysis. Addition of plasma fibrinogen to a SCD risk 
prediction model containing established risk factors did not significantly improve risk discrimination, but 
improved the net reclassification. 
Conclusions: Available data suggest fibrinogen is positively, log-linearly, and independently associated 
with risk of SCD. Further research is needed to assess the potential relevance of plasma fibrinogen 
concentrations in SCD prevention. 
 
Keywords: fibrinogen; inflammation; sudden cardiac death; non-sudden cardiac death; regression dilution 
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1. Introduction 
Sudden cardiac death (SCD) is a common manifestation of coronary heart disease (CHD) in the 
general population and is a global public health problem accounting for 15-20% of all deaths.1, 2 Over the 
past decades, there has been a progressive decline in CHD due to major advances in treatment and 
preventive measures; in contrast, SCD rates have declined to a lesser extent.3 Though atherosclerotic 
cardiovascular disease (CVD) risk factors explain a large proportion of the risk for SCD,4, 5 its 
pathogenesis is still not fully established. This emphasizes the need to better understand the epidemiology 
of SCD and evaluate the relevance of other potential risk factors. 
Inflammation plays a central role in the development and progression of atherothrombosis. 6  
Emerging evidence indicates that inflammation may also be linked to the risk of SCD. Cardiac rhythm 
disturbances (particularly ventricular arrhythmias) are considered to be the leading events behind SCDs 
from atherothrombotic occlusion of coronary arteries;7 and inflammation has also been implicated in the 
pathogenesis of cardiac arrhythmias.8 Systemic markers of inflammation such as C-reactive protein 
(CRP), albumin, and interleukin-6 (IL-6) have been demonstrated to be associated with SCD in the 
general population.9-12 Fibrinogen, an inflammatory marker, a major coagulation protein in the blood, and 
an important determinant of blood viscosity and platelet aggregation,13, 14 is a risk factor for vascular 
events 15 and has been demonstrated to be linked to cardiac arrhythmias;16 however, its association with 
SCD is uncertain. A number of studies have reported on the associations of fibrinogen with SCD in 
angina patients,17, 18 but only two prospective studies have so far reported on the associations between 
baseline plasma fibrinogen levels and SCD risk in apparently healthy participants and their results have 
been inconsistent. Whereas one study showed a positive association,11 the other study found no 
association,9 giving rise to uncertainty regarding the nature of the association. Out-of-hospital SCD is an 
unrecognized yet major contributor to SCDs, however, no study has at yet assessed the association of 
4 
 
fibrinogen with out-of-hospital SCDs. Finally, the long-term relevance of fibrinogen to SCD is unknown. 
This is particularly important, given that fibrinogen has been shown to exhibit high within-person 
variability19 as a result of measurement errors, fluctuations due to acute phase reactions, lifestyle changes, 
and chronic disease.20 Given the established role of inflammation in the development of CHD, we 
hypothesized that elevated levels of plasma fibrinogen may be independently associated with an increased 
risk of SCD in the general population. Against this background, we aimed to evaluate in detail the nature 
and magnitude of the prospective association of fibrinogen with risk of SCD (in- and out-of-hospital 
SCDs) in a population-based cohort of 1773 apparently healthy men from eastern Finland. Repeat 
measurements of fibrinogen were performed 4 and 11 years after the baseline measurements in 959 
participants to help quantify within-person variability in fibrinogen levels. To put our results into 
perspective, we also examined the association of fibrinogen with non-SCD. Finally, to contextualize the 
associations, we also performed a pooled analysis of the available prospective evidence on the 
associations. 
 
2. Methods 
2.1. Participants 
The study population comprised of a representative sample of men living in the city of Kuopio and its 
surrounding rural communities in eastern Finland. Subjects were participants in the Kuopio Ischaemic 
Heart Disease (KIHD) risk factor study, a population-based prospective cohort study designed to 
investigate risk factors for CVD and related outcomes.21 Of the 3433 randomly selected men who were 
potentially eligible, 2682 (78%) volunteered to participate in the study. Participants were 42-61 years of 
age during baseline examinations performed between March 1984 and December 1989. For the present 
analyses, men with a prevalent history of heart failure or cardiac arrhythmias were excluded leaving a 
final cohort of 1773 men with non-missing information on plasma fibrinogen, relevant covariates, and 
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SCD outcomes. The Research Ethics Committee of the University of Eastern Finland approved the KIHD 
study, and each participant gave written informed consent.  
 
2.2. Ascertainment of outcomes 
In the KIHD study, participants are under continuous surveillance for the development of new CVD 
events, including incident cases and deaths.22 There were no losses to follow-up and all SCDs that 
occurred from study enrollment through 2012 were included. The sources of information on SCD 
outcomes were based on a comprehensive review of all available hospital records, wards of health 
centres, informant interviews, health practitioner questionnaires, medico-legal reports, and death 
certificate registers. Deaths were coded according to ICD-9 codes or ICD-10 codes. The diagnostic 
classification of SCDs was based on symptoms, electrocardiographic findings, cardiac enzyme elevations, 
autopsy findings (80% of all cardiac deaths), and history of CHD together with the clinical history and 
findings from hospital and paramedic staff. A death was determined to be an SCD when it occurred 
within 1 hour of the onset of an abrupt change in symptoms or within 24 hours after the onset of 
symptoms; including nonwitnessed cases when clinical and autopsy findings did not reveal a non-cardiac 
cause of sudden death or after successful resuscitation from ventricular tachycardia and/or ventricular 
fibrillation.23 The witnessed subject was to have been seen alive and symptom free within 1 hour before 
the event. Sudden cardiac deaths that occurred in out-of-hospital conditions were also defined as events 
that occurred in places that had been reported accurately in hospital documents.23 Documents were cross-
checked in detail by two physicians. Non-SCDs were also carefully documented using standardized 
criteria. Cardiac deaths that did not lead to death during the following 24 hours of the onset of symptoms 
were considered as non-SCDs. The Independent Events Committee, masked to clinical data, performed 
classification of deaths. 
 
 
6 
 
2.3. Measurement of risk factors 
Collection of blood specimens, data on socio-demographics, physical measurements, vascular risk 
factors, and the measurement of serum lipids and glucose have been described previously.24 In addition to 
an overnight fast, participants were instructed to abstain from drinking alcohol for at least three days and 
from smoking for at least 12 hours prior to assessment. Blood samples were taken between 08:00 and 
10:00 hours following rest in the supine position for 30 minutes. The serum samples were stored frozen at 
-80 °C for 0.2-2.5 years. Plasma fibrinogen concentrations were determined in fresh plasma samples with 
excess thrombin using the Coagulometer KC4 device (Heinrich Amelung GmbH, Lemgo, Germany). The 
coefficient of variation describing the day-to-day measurement of variability for fibrinogen assays was 
5.5 percent. Repeat measurements of fibrinogen were performed 4 years and 11 years after baseline 
during a 22 year period in a random subset of participants. C-reactive protein (CRP) was measured with 
an immunometric assay (Immulite High Sensitivity C-Reactive Protein Assay; DPC, Los Angeles, CA, 
USA). History of diabetes was defined as having a clinical diagnosis of diabetes and regular treatment 
with diet, oral hypoglycaemic agents or insulin therapy, fasting plasma glucose  ≥ 7.0 mmol/l, or 
according to self-reports. Standard resting 12-lead ECG was also recorded. The ECG criterion for left 
ventricular hypertrophy (LVH) was based on either the Sokolow-Lyon or Romhilt-Estes point score.25-28 
 
2.4. Statistical analyses 
Prospective cohort analyses Values of skewed variables were log-transformed to achieve 
approximately symmetrical distributions. We performed descriptive analyses summarising the baseline 
characteristics of the participants. Cross-sectional associations of fibrinogen with various risk markers 
were assessed using calculated partial correlation coefficients (adjusted for age). All analyses were 
conducted using Cox proportional hazard models. The proportional hazards assumptions were tested as 
previously described and satisfied.29 To quantify and correct for within-person variability in levels of 
fibrinogen, that is, the extent to which an individual’s fibrinogen measurements vary around a long-term 
7 
 
average level exposure (“usual levels”),19 adjusted regression dilution ratios (RDRs) were estimated by 
regressing available repeat measurements on baseline values.30 The RDR assumed that the “usual levels” 
of fibrinogen represented the true long-term exposure of fibrinogen levels on SCD risk.31 To characterize 
shapes of associations, hazard ratios (HRs) were calculated within quartiles of baseline fibrinogen levels 
relative to the bottom quartile and plotted against mean fibrinogen levels in each quartile using floating 
absolute risks.32 As the association showed a log-linear shape, HRs were calculated per 1 standard 
deviation (SD) higher loge fibrinogen levels. The SD of baseline loge fibrinogen was 0.18 (equivalent to 
approximately one-fold higher circulating fibrinogen, as e0.18=1.19). Hazard ratios were adjusted for age, 
BMI, systolic blood pressure (SBP), prevalent CHD, smoking status, history of diabetes mellitus, LVH, 
history of hypertension, use of medications (antihypertensive agents and lipid-lowering drugs), alcohol 
consumption, resting heart rate, triglycerides, total cholesterol, high-density lipoprotein cholesterol (HDL-
C), and CRP. Formal tests of interaction were used to assess statistical evidence of effect modification by 
pre-specified clinically relevant characteristics, such as age at survey, BMI, SBP, CRP, history of 
diabetes, smoking status, history of hypertension, history of CHD, and use of anti-hypertensive agents. To 
avoid including cases with prevalent but undetected CHD, heart failure, and cardiac arrhythmias (which 
are direct causes of SCD), sensitivity analysis involved excluding the first five years of follow-up. To 
assess whether adding information on plasma fibrinogen measurements to documented established risk 
factors is associated with improvement in prediction of SCD risk, we calculated measures of 
discrimination for censored time-to-event data (Harrell’s C-index 33) and reclassification (the continuous 
net-reclassification-improvement [NRI], a category-free version of the NRI).34 Measures of 
discrimination and reclassification were assessed for the risk model (age, SBP, cigarette smoking, serum 
low density lipoprotein cholesterol, history of diabetes, BMI, previous myocardial infarction, and family 
history of CHD) as previously described.23, 35 
Meta-analysis We conducted a meta-analysis of published studies reporting on the association 
between fibrinogen and SCD. Prospective (cohort or nested case-control) studies of the association 
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between fibrinogen and SCD that were published up to September 2015 were sought using computer-
based databases (MEDLINE, EMBASE, and Science Citation Index). The computer-based searches 
combined free and MeSH search terms and combined key words related to fibrinogen (e.g., “fibrinogen”, 
“inflammation”) and sudden cardiac death (e.g., “sudden cardiac death”, “cardiac death”). There were no 
restrictions on language or the publication date. The details of the search strategy are presented in 
Appendix Supplement 1. The relative risk (RR) with 95% CIs was used as the summary measure of 
association across studies. To enable a consistent approach to the meta-analysis and enhance 
comparability, reported study-specific RRs were also transformed to per 1SD change in baseline 
fibrinogen values using standard statistical methods 36, 37 which have been described in detail 
previously.38, 39 Associations of usual levels of fibrinogen and SCD were estimated using the correction 
factor derived from the KIHD Study. The summary RR (including the estimate from the present study) 
was calculated using fixed effects meta-analysis. Statistical heterogeneity across studies was quantified 
using standard chi-square tests and the I2 statistic.40  All statistical analyses were conducted using Stata 
version 14 (Stata Corp, College Station, Texas). 
 
3. Results 
3.1. Baseline characteristics and correlates of fibrinogen 
Table 1 summarizes baseline characteristics of the 1773 participants in the present study. Mean (SD) 
loge fibrinogen concentration was 1.09 (0.18) g/l. During an average follow-up of 22 years, there were 
131 SCDs (annual rate 3.35/1,000 person-years at risk; 95% CI: 2.83 to 3.98). Of the total SCDs, 101 
occurred out-of-hospital. Plasma fibrinogen levels were weakly and positively correlated with 
questionnaire and physical measures (age, alcohol consumption, BMI, blood pressure, and resting heart 
rate) and with several lipid and metabolic markers. A strong positive correlation was observed for loge 
CRP (r = 0.55) and weak inverse correlations observed for HDL-C (r = -0.10) and creatinine (r = -0.12). 
Baseline fibrinogen concentrations were higher in people with diabetes compared with people without 
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diabetes and higher in current smokers compared with non-smokers (Table 2). 
 
3.2. Correction for within-person fibrinogen variability 
Repeat measurements of fibrinogen taken 4 years and 11 years after baseline over 22 years were 
available in a random sample of 959 men, providing a total of 1,277 repeat measurements of fibrinogen. 
Overall, the RDR of loge fibrinogen, adjusted for age, was 0.48 (95% CI: 0.41 to 0.55), suggesting that 
the associations using one-off or baseline measurements of fibrinogen with SCD will be about half as 
strong as they otherwise would be using usual levels of fibrinogen. The within-person variability of 
fibrinogen was comparable to what has been previously reported.19 
 
3.3. Fibrinogen and risk of sudden cardiac death 
Prospective cohort analysis Cumulative hazard curves demonstrated a greater risk of new-onset SCDs 
among males in the top quartile of fibrinogen levels compared to those in the bottom quartile (P for log-
rank test= 0.0001; Figure 1). Baseline and usual fibrinogen levels were log-linearly associated with risk 
of SCD in analyses adjusted for conventional risk factors (age, BMI, SBP, prevalent CHD, smoking 
status, history of diabetes mellitus, LVH, history of hypertension, use of antihypertensive agents and 
lipid-lowering drugs) and potential confounders (alcohol consumption, resting heart rate, triglycerides, 
total cholesterol, HDL-C, and CRP) (Figures 2-3). The age-adjusted HR per 1 SD change in baseline loge 
fibrinogen level was 1.59 (95% CI: 1.36 to 1.87; P < 0.001), which was attenuated following further 
adjustment for conventional risk factors 1.32 (95% CI: 1.11 to 1.57; P = 0.002). The results remained 
consistent on further adjustment for several potential confounders 1.30 (95% CI: 1.09 to 1.56; P = 0.004). 
The corresponding HRs per 1 SD change in usual loge fibrinogen levels were 2.64 (95% CI: 1.89 to 3.70; 
P < 0.001), 1.80 (95% CI: 1.25 to 2.58; P = 0.002), and 1.74 (95% CI: 1.20 to 2.52; P = 0.004) 
respectively. The HRs remained unchanged after further adjusting for CRP and accounting for incident 
coronary events (Table 3). The HR for SCD per 1 SD change in baseline loge fibrinogen level in age-
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adjusted analysis was 1.59 (95% CI: 1.36 to 1.87; P < 0.001), which was minimally attenuated after 
single adjustment for prevalent CHD 1.53 (95% CI: 1.30 to 1.80; P < 0.001) and remained unchanged on 
further adjustment for incident coronary events 1.50 (95% CI: 1.28 to 1.77; P < 0.001). HRs did not vary 
importantly by levels or categories of pre-specified conventional risk factors (Figure 4), and the main 
results remained the same in analyses that excluded the first five years of follow-up (data not shown). To 
put the strength of the association of fibrinogen with risk of SCD into context, comparisons were made to 
associations of fibrinogen with acute myocardial infarction (AMI) and ventricular arrhythmias (VAs). 
The initial positive association of fibrinogen with risk of AMI in analyses adjusted for several established 
and emerging risk factors was attenuated on further adjustment for CRP. There was no statistically 
significant evidence of an association with VAs (Appendix Supplement 2). Addition of CRP 
measurements alone to a SCD risk prediction model increased the C-index significantly by 0.0171 (95% 
CI: 0.0037 to 0.0304; P=0.012) and yielded a NRI of 37.7% (10.9 to 64.4%, P=0.006). When information 
on plasma fibrinogen measurements alone was added to the prediction model, the C-index change was 
0.0128 (-0.0063 to 0.0319; P=0.188) and NRI was 54.6% (28.4 to 80.9%, P<0.001). On addition of 
information on both CRP and fibrinogen measurements to the model, the C-index increased significantly 
by 0.0140 (0.0006 to 0.274; P=0.041) and the NRI was 33.1% (7.4 to 58.7%, P=0.011). 
In separate analyses for out-of-hospital SCDs, the initial positive association of fibrinogen with out-of-
hospital SCDs in age-adjusted analyses was less robust upon further adjustment for established risk 
factors and potential confounders, however, became stronger with further adjustment for CRP.  
For non-SCDs, the age-adjusted HR per 1 SD change in baseline loge fibrinogen level was 1.61 (95% 
CI: 1.26 to 2.04; P < 0.001), which was attenuated following further adjustment for conventional risk 
factors 1.41 (95% CI: 1.09 to 1.84; P = 0.010). The results remained consistent on further adjustment for 
several potential confounders, CRP, and accounting for incident coronary events 1.39 (95% CI: 1.02 to 
1.91; P = 0.039) (Table 3).   
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Literature-based meta-analysis Including the current study, we identified three population-based 
prospective studies reporting on the associations between plasma fibrinogen and risk of SCDs and non-
SCDs (Appendix Supplement 3).9, 11 In pooled fixed effects analysis involving 25 553 participants and 
388 SCD events, the RRs for SCD per 1 SD higher baseline and usual fibrinogen levels, typically 
adjusted for several conventional and potential risk factors for SCD were 1.42 (95% CI: 1.25 to 1.61; P < 
0.001) and 2.07 (95% CI: 1.59 to 2.69; P < 0.001) respectively (I2=2.0%, 95% CI: 0-90%; P=0.359) 
(Appendix Supplement 4). For pooled analysis of 269 non-SCDs, the corresponding RRs were 1.40 
(95% CI: 1.21 to 1.63; P < 0.001) and 2.02 (95% CI: 1.47 to 2.76; P < 0.001), with no evidence of 
heterogeneity between studies (Appendix Supplement 5). 
 
4. Discussion 
4.1. Key findings 
Our findings in the KIHD cohort comprising middle-aged to older men without a history of HF or 
cardiac arrhythmias at baseline, provide several relevant findings that have not been previously reported. 
Indeed, fibrinogen was strongly correlated with CRP as expected and there were generally weak 
associations with several cardiovascular risk markers. In analyses adjusted for several established and 
emerging risk factors, we observed log-linear associations of baseline and usual levels of fibrinogen with 
risk of SCD. The association did not materially change on further adjustment for a comprehensive panel 
of potential confounders and remained consistent on additional adjustment for CRP. The fibrinogen-SCD 
association remained materially unchanged after adjusting for prevalent CHD and incident coronary 
events in analysis initially only adjusted for age. The overall findings remained generally consistent 
(albeit imprecise estimates for the categories with lower event rates) across several subgroups and levels 
of cardiovascular risk markers. The associations were similar for non-SCDs. Our finding of a significant 
evidence of an association of fibrinogen with SCD is consistent with a previous report from the 
Atherosclerosis Risk in Communities (ARIC) study,11 but in contrast to the lack of an association 
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observed in the the Etude PRospective de l’Infarctus du Myocarde (PRIME) study.9 Differences in 
statistical power may explain the apparently contradictory results. There was a lower event rate in the 
PRIME study (50 SCDs) compared to our study and that of the ARIC study. A significant association 
with out-of-hospital SCDs was observed in age-adjusted analyses, but was attenuated after adjustment for 
established risk factors. There was a negative confounding effect of CRP on the association which was 
not expected, given the strong positive correlation of fibrinogen with CRP. Furthermore, pooled analysis 
of risk estimates from the three studies (including ours) reinforce the validity and generalizability of these 
new data. Finally, our analyses indicate that addition of information on plasma fibrinogen measurements 
to risk factors for SCD did not incrementally improve SCD risk prediction, but yielded a significant 
improvement in reclassification. 
 
4.2. Possible explanations for findings 
The current findings highlight and lend further support to the inflammatory hypothesis involved in the 
development of CHD, the major pathology underlying SCD. Indeed, pathological signs of inflammation 
have been demonstrated in the coronary atherosclerotic lesions which are found in majority of cases of 
SCD.41, 42 This inflammatory hypothesis has also been evaluated in several population-based cohort 
studies and it has been demonstrated that systemic inflammatory markers such as CRP, IL-6, albumin, 
and white blood cell counts are robustly associated with SCDs.9-11, 43 However, our observed fibrinogen-
SCD association remained robust after adjusting for CRP (the most commonly used marker of low-grade 
chronic inflammation), which supports the hypothesis that other pathways apart from inflammatory 
processes may also play a role in the etiology between fibrinogen and SCDs. In our study, we observed 
that the significant association of fibrinogen with AMI was attenuated on further adjustment for CRP, 
which also reflects the possibility that inflammatory mechanisms mainly underlie the etiological 
association between fibrinogen and CHD, but not between fibrinogen and SCD. In line with the 
coagulative properties of fibrinogen in blood and it being an important determinant of blood viscosity and 
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platelet aggregation,13, 14 other potential pathways have been postulated. These include endothelial 
injury,17 the formation of low permeability fibrin clot in association with elevated fibrinogen levels,44 
thrombosis,45 abnormalities of  blood flow,46 platelet hyperactivity,47 and the contribution of fibrinogen to 
the development of subclinical atherosclerosis which eventually leads to SCD.10, 48 Additionally, it has 
been suggested that fibrinogen may contribute directly to the onset of arrhythmias, which often lead to 
SCD in the presence of underlying CHD.5, 49 The involvement of fibrinogen in arrhythmogenesis has been 
attributed to pathways associated with the inflammatory cascade and hemodynamic alterations.50, 51 
Fibrinogen may also cause acute myocardial ischemia, which is the most common trigger for fatal 
arrhythmias.52 Our study, however, did not demonstrate any statistically significant evidence of an 
association between fibrinogen and VAs, which may be attributed to the low event rate. 
Collectively, the present study establishes a robust observational association between fibrinogen and 
SCD risk. Although this does not establish causality, the linear and independent relationship is suggestive 
of causality. Establishing causality will require research designs that can minimize potential residual 
biases, such as rigorous randomized controlled trials of selective fibrinogen-lowering agents or Mendelian 
randomisation (MR) studies of genetic variants specifically related to fibrinogen levels.53  
 
4.3. Implications of findings 
Our findings demonstrate a clear and independent link between plasma fibrinogen and SCD risk, 
which may have potential clinical implications. Our findings of no incremental improvement in SCD 
prediction on addition of information on plasma fibrinogen to a risk prediction score, does not rule out the 
potential for fibrinogen assays to be used in the identification of individuals at high risk for SCD.  There 
was a net reclassification improvement and our risk prediction analyses were limited as we did not have 
complete measurements on several risk factors (e.g., ECG parameters, measures of heart rate variability, 
measures of ejection fraction, and angiographic findings) used in standard risk prediction algorithms for 
SCD.54-57 Given the robust and independent long-term association demonstrated between baseline levels 
14 
 
of fibrinogen and risk of SCD and the ease and simplicity of measuring fibrinogen assays, plasma 
fibrinogen remains a promising though unproven strategy for SCD risk prevention and its potential 
usefulness in SCD risk prediction deserves further investigation. Although the causal nature of the 
fibrinogen-SCD association has not been established, there remains a possibility that lowering or 
modification of plasma levels of fibrinogen may decrease the risk of future SCD, given that plasma 
fibrinogen levels can be considerably reduced by lifestyle interventions such as regular exercise and 
smoking cessation, which also affect levels of established vascular risk factors.15 Our reproducibility 
substudies of fibrinogen measurements in the KIHD study and findings from the Fibrinogen Studies 
Collaboration19 indicate a high within-person variability in fibrinogen levels. This suggests that analyses 
using only single baseline measurements of fibrinogen underestimates the associations substantially as we 
have demonstrated. The poor reproducibility of fibrinogen may therefore limit its utility as a reliable risk 
indicator in clinical practice based on just a single baseline measurement. Formal risk assessment 
analyses involving large-scale individual participant data are warranted to assess the potential clinical 
utility of fibrinogen as a risk assessment tool for SCD. 
 
4.4. Strengths and limitations 
We had the advantage of a large sample that was selected to be a nationally representative population-
based sample of middle-aged men, was well characterised, involved high response rates and there were no 
losses during follow-up. Participants have been prospectively and annually monitored using established 
hospital databases and supplemented with reliable data on a comprehensive panel of lifestyle and 
biological markers to allow adequate adjustment for potential confounding. The mean follow-up period 
was sufficiently long to ascertain the risk for SCD in the general population. Serial measurements of 
fibrinogen made within a subset of individuals over time were available, enabling quantification of the 
extent of within-person variability over the long period of follow-up. All previous epidemiological studies 
on fibrinogen and SCD risk were not able to correct for fibrinogen variability, potentially yielding biased 
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estimates. The KIHD study made such a correction on the basis of two repeated measurements, indicating 
an independent association of fibrinogen with SCD. The reliability of the data was also confirmed by our 
ability to replicate the independent association of fibrinogen with non-SCD.9, 11 Another limitation was 
the small number of SCD events. Though repeat measurements of fibrinogen several years apart enabled 
correction for long-term within-person variability, we were unable to account for short-term variability, 
such as seasonal or diurnal fluctuations.58, 59 In addition, repeat measurements of fibrinogen were only 
made within a subset of men; therefore studies are needed with repeat measurements of fibrinogen in 
larger numbers of participants to assess fibrinogen variability in greater detail. Considering that 
fibrinogen levels were correlated with the several established and emerging risk factors we adjusted for 
and the fact that we only had repeat measurements of fibrinogen, there is a possibility of biases in either 
direction for our observed association between long-term average levels of fibrinogen and SCD.60 
However, this is unlikely for the following reasons: i) with the exception of the strong correlation with 
CRP, fibrinogen was weakly correlated with several established and emerging risk factors, which 
suggests the scope for minimal confounding for the association as we have demonstrated and ii) after 
adjustment for established risk factors, the association remained essentially consistent following 
additional adjustment for several potential confounders such as lipids and CRP. Though we adjusted for a 
comprehensive panel of confounders, there is still a possibility of potential residual confounding due to 
errors in risk marker measurements and other unmeasured confounders [such as IL-6, white blood cell 
counts, von Willebrand factor, class of anti-hypertensives, and use of anti-inflammatory drugs (e.g. 
aspirin), anticoagulants (e.g., warfarin), or hypoglycemic agents]. We also acknowledge that the study 
included only relatively middle-aged Caucasian men and therefore the associations demonstrated cannot 
necessarily be extrapolated to older men (> 61 years), women and other ethnicities. This is particularly 
important as fibrinogen exhibits considerable variability within individuals over time as a result of the 
dynamics of lifestyle factors as well as ageing.20 Finally, the limited number of studies for the meta-
analysis precluded the ability to adequately quantify heterogeneity (evidenced by the wide confidence 
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intervals for heterogeneity estimates) and explore this between contributing studies. Additional larger-
scale prospective studies with relevant data may be needed to confirm our findings. 
 
5. Conclusions 
Available data suggest fibrinogen is positively, log-linearly, and independently associated with future risk 
of SCD in the general male population. Further research is needed to replicate these findings and assess 
the potential relevance of plasma fibrinogen concentrations in SCD prevention. 
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Table 1. Baseline participant characteristics 
  
Overall (N=1773) 
Mean (SD) or median 
(IQR) OR n (%) 
 
Without SCD (N=1642) 
Mean (SD) or median 
(IQR) or n (%) 
 
With SCD (N=131) 
Mean (SD) or median 
(IQR) n (%) 
 
 
P-value 
     
Fibrinogen (g/l) 2.96 (2.62-3.32) 2.93 (2.61-3.30) 3.19 (2.87-3.57) < 0.0001 
     
Questionnaire/Prevalent conditions     
Age at survey (years) 52.3 (5.3) 52.3 (5.3) 53.7 (4.2) 0.002 
Alcohol consumption (g/week) 76.8 (144.2) 75.3 (144.9) 95.3 (134.9) 0.126 
History of diabetes 82 (4.6) 69 (4.2) 13 (9.9) 0.003 
Current smokers 562 (31.7) 500 (30.5) 62 (47.3) < 0.001 
Left ventricular hypertrophy 20 (1.1) 19 (1.2) 1 (0.8) 0.681 
History of hypertension 506 (29) 465 (28.3) 41 (31.3) 0.468 
History of CHD 373 (21.0) 321 (19.6) 52 (39.7) < 0.001 
Use of anti-hypertensives 319 (18.0) 283 (17.2) 36 (27.5) 0.003 
Medication for dyslipidemia 10 (0.6) 10 (0.6) 0 (0.0) 0.370 
     
Physical measurements     
BMI (kg/m2) 26.9 (3.5) 26.8 (3.4) 28.0 (4.3)  0.0001 
SBP (mmHg) 133.7 (16.3) 133.4 (16.1) 137.9 (17.3) 0.002 
DBP (mmHg) 89.2 (10.4) 89.0 (10.4) 91.2 (10.2) 0.023 
Resting heart rate (bpm) 62.4 (10.7) 62.3 (10.6) 64.0 (11.7) 0.069 
     
Lipid markers     
Total cholesterol (mmol/l) 5.91 (1.08) 5.89 (1.08) 6.16 (1.12) 0.006 
HDL-C (mmol/l) 1.29 (0.30) 1.29 (0.30) 1.23 (0.26) 0.022 
Triglycerides (mmol/l) 1.10 (0.80-1.55) 1.09 (0.79-1.52) 1.13 (0.85-1.63) 0.034 
     
Metabolic and inflammatory 
markers 
    
Fasting plasma glucose (mmol/l) 5.32 (1.23) 5.29 (1.16) 5.69 (1.87) 0.0004 
Serum creatinine (µmol/1) 89.2 (13.4) 89.5 (13.3) 85.7 (13.2) 0.0026 
CRP (mg/l) 1.22 (0.69-2.25) 1.19 (0.67-2.18) 1.74 (0.92-3.09) 0.0001 
 
 BMI, body mass index; CHD, coronary heart disease; CRP, C-reactive protein; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein 
cholesterol; SD, standard deviation; SBP, systolic blood pressure; SCD, sudden cardiac death 
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Table 2. Cross-sectional correlates of fibrinogen 
 
Pearson correlation 
r (95% CI)† 
Percentage difference (95% CI) in fibrinogen 
levels per 1 SD higher or compared to 
reference category of correlate‡ 
Loge fibrinogen (g/l) - - 
   
Questionnaire/Prevalent conditions   
Age at survey (yrs) 0.16 (0.11, 0.20)*** 3% (2, 4)*** 
Alcohol consumption (g/week) 0.12 (0.08, 0.17)*** 2% (1, 3)*** 
History of diabetes   
    No - Ref 
    Yes - 6% (2, 11)* 
Smoking status   
    Other - Ref 
    Current - 12% (11, 14)*** 
Left ventricular hypertrophy   
    No - Ref 
    Yes - 8% (-1, 17) 
History of hypertension   
    No - Ref 
    Yes - 1% (-0, 3) 
History of CHD   
    No - Ref 
    Yes - 5% (3, 7)*** 
Use of anti-hypertensives   
    No - Ref 
    Yes - 3% (1, 6)* 
Medication for dyslipidemia   
    No - Ref 
    Yes - 10% (-2, 23) 
   
Physical measurements   
BMI (kg/m2) 0.12 (0.07, 0.16)*** 2% (1, 3)*** 
SBP (mmHg) 0.03 (-0.01, 0.08)* 1% (-0, 1) 
DBP (mmHg)   
Resting heart rate (bpm) 0.09 (0.05, 0.14)*** 2% (1, 3)*** 
   
Lipid markers   
Total cholesterol (mmol/l) 0.11 (0.07, 0.16)*** 2% (1, 3)*** 
HDL-C (mmol/l) -0.10 (-0.15, -0.05)*** -2% (-3, -1)*** 
Loge triglycerides (mmol/l) 0.10 (0.06, 0.15)*** 2% (1, 3)*** 
   
Metabolic and inflammatory markers   
Fasting plasma glucose (mmol/l) 0.09 (0.05, 0.14)*** 2% (1, 3)** 
Serum creatinine (µmol/1) -0.12 (-0.17, -0.07)*** -2% (-3, -1)*** 
Loge C-reactive protein (mg/l) 0.55 (0.51, 0.58)*** 10% (10, 11)*** 
 
 BMI, body mass index; CHD, coronary heart disease; DBP, diastolic blood pressure; HDL-C, high-density lipoprotein cholesterol; SD, standard 
deviation; SBP, systolic blood pressure; †Pearson correlation coefficients between loge fibrinogen and the row variables; ‡, Percentage change in 
fibrinogen levels per 1-SD increase in the row variable (or for categorical variables, the percentage difference in mean fibrinogen levels for the 
category versus the reference) adjusted for age; asterisks indicate the level of statistical significance: *, p<0.05; **, p<0.01; ***, p<0.001 
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Table 3. Associations of baseline and usual fibrinogen levels with sudden cardiac deaths, out-of-hospital 
sudden cardiac deaths, and nonsudden cardiac deaths 
 
Models Sudden cardiac death  Out-of-hospital 
sudden cardiac death 
 Non-sudden cardiac 
death 
 
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
 1773 participants and  
131 cases 
 1773 participants and  
101 cases 
 1773 participants and  
61 cases 
 
Baseline fibrinogen 
Model 1 1.59 (1.36 to 1.87) < 0.001 1.43 (1.19 to 1.73) < 0.001 1.61 (1.26 to 2.04) < 0.001 
Model 2 1.32 (1.11 to 1.57) 0.002 1.20 (0.98 to 1.46) 0.076 1.41 (1.09 to 1.84) 0.010 
Model 3 1.30 (1.09 to 1.56) 0.004 1.18 (0.97 to 1.45) 0.106 1.40 (1.08 to 1.83) 0.012 
Model 4 1.32 (1.07 to 1.62) 0.010 1.28 (1.01 to 1.63) 0.040 1.42 (1.04 to 1.93) 0.027 
Model 5 1.31 (1.06 to 1.62) 0.011 1.28 (1.01 to 1.62) 0.043 1.39 (1.02 to 1.91) 0.039 
Usual fibrinogen 
Model 1 2.64 (1.89 to 3.70) < 0.001 2.12 (1.43 to 3.13) < 0.001 2.69 (1.63 to 4.43) < 0.001 
Model 2 1.80 (1.25 to 2.58) 0.002 1.45 (0.96 to 2.20) 0.076 2.06 (1.19 to 3.55) 0.010 
Model 3 1.74 (1.20 to 2.52) 0.004 1.42 (0.93 to 2.16) 0.106 2.03 (1.17 to 3.53) 0.012 
Model 4 1.78 (1.15 to 2.74) 0.010 1.68 (1.02 to 2.75) 0.040 2.06 (1.09 to 3.92) 0.027 
Model 5 1.76 (1.14 to 2.73) 0.011 1.67 (1.02 to 2.75) 0.043 1.99 (1.03 to 3.85) 0.039 
 
 
Hazard ratios are reported per 1 standard deviation increase in loge fibrinogen levels 
Model 1: Adjusted for age 
Model 2: Model 1 plus body mass index, systolic blood pressure, prevalent coronary heart disease, smoking status, history of 
diabetes, left ventricular hypertrophy, history of hypertension, and use of medications (antihypertensive agents and lipid-lowering 
drugs) 
Model 3: Model 2 plus alcohol consumption, resting heart rate, triglycerides, total cholesterol, and high-density lipoprotein 
cholesterol 
Model 4: Model 3 plus C-reactive protein 
Model 5: Model 4 plus incident coronary heart disease as a time-dependent covariate 
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Figure 1. Cumulative hazard curves for sudden cardiac death by quartiles of fibrinogen 
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The median fibrinogen level (g/l) was 2.42 (range 1.78-2.62) for the lowest quartile; 2.79 (range 2.62-
2.96) for the second quartile; 3.13 (range 2.96-3.32) for the third quartile; and 3.64 (range 3.33-5.96) for 
the top quartile; SCD, sudden cardiac death 
 
 
 
 
 
 
26 
 
Figure 2. Hazard ratios for sudden cardiac death, by quartiles of baseline levels of loge fibrinogen 
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A, adjusted for age; B, adjusted for age, body mass index, systolic blood pressure, prevalent coronary 
heart disease, smoking status, history of diabetes, left ventricular hypertrophy, history of hypertension, 
and use of medications (antihypertensive agents and lipid-lowering drugs); C, adjusted for B plus alcohol 
consumption, resting heart rate, triglycerides, total cholesterol, and high-density lipoprotein cholesterol; 
D, adjusted for C plus C-reactive protein 
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Figure 3. Hazard ratios for sudden cardiac death, by quartiles of usual levels of loge fibrinogen 
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A, adjusted for age; B, adjusted for age, body mass index, systolic blood pressure, prevalent coronary 
heart disease, smoking status, history of diabetes, left ventricular hypertrophy, history of hypertension, 
and use of medications (antihypertensive agents and lipid-lowering drugs); C, adjusted for B plus alcohol 
consumption, resting heart rate, triglycerides, total cholesterol, and high-density lipoprotein cholesterol; 
D, adjusted for C plus C-reactive protein 
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Figure 4. Hazard ratios for baseline and usual loge fibrinogen and sudden cardiac death risk by several 
participant level characteristics 
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1.18 (0.82, 1.70)
HR (95% CI)
1.5 .75 1.5 2.5
HR (95% CI) per 1 SD higher log
e
Fibrinogen levels
1.93 (1.22, 3.05)
1.77 (1.02, 3.07)
1.94 (1.07, 3.52)
1.79 (1.14, 2.80)
1.46 (0.81, 2.62)
1.94 (1.23, 3.06)
2.94 (1.34, 6.45)
1.35 (0.86, 2.12)
1.90 (1.30, 2.79)
1.15 (0.41, 3.23)
2.18 (1.33, 3.58)
1.46 (0.87, 2.44)
1.73 (1.13, 2.63)
2.00 (1.01, 3.98)
1.83 (1.15, 2.93)
1.75 (1.01, 3.02)
1.92 (1.28, 2.87)
1.41 (0.67, 2.98)
HR (95% CI)
.808
.82
.429
.09
.370
.266
.714
.899
.471
P-value*
1.5 .75 2.5 5 7.5
HR (95% CI) per 1 SD higher usual log
e
Fibrinogen levels
(B)(A)
 
A, baseline levels of fibrinogen; B, usual levels of fibrinogen; hazard ratios were adjusted for age, body 
mass index, systolic blood pressure, prevalent coronary heart disease, smoking status, history of diabetes, 
left ventricular hypertrophy, history of hypertension, and use of medications (antihypertensive agents and 
lipid-lowering drugs); CI, confidence interval; HR, hazard ratio; SCDs, sudden cardiac deaths; SD, 
standard deviation; SBP, systolic blood pressure; *, P-value for interaction; cut-offs used for age, body 
mass index, systolic blood pressure, and C-reactive protein are median values. 
 
